

PharmaMar Group reports first quarter financial results

- First quarter revenues of €44.7 million
- Yondelis[®] sales amounted to €18.4 million in the first quarter of 2018
- Improved net attributable income compared to the same period of 2017

Madrid, 26th of April, 2018: The PharmaMar Group (MSE: PHM) reported €44.7 million in total revenues in the first quarter of 2018, compared with €45.5 million in the same period of 2017. Of that figure, €18.4 million were related to sales of Yondelis[®], compared to €22.5 million in the same period of the previous year. The difference was mainly due to the fact that a major order from the Scandinavian distributor was shifted to the second quarter. Consequently, that volume will be recovered in the following months. Other factors that contributed to this difference in quarterly revenues were the fact that there were no sales of raw material to partners Janssen and Taiho in 1Q18, contrasting with €1.4 million in the same period of the previous year, and also price erosion in some European countries.

Revenues in the Consumer Chemicals division totaled \in 16.8 million in the first quarter of 2018, compared with \in 17.4 million in the same period last year. This slight difference was mainly due to the fact that the distributors delayed their summer insecticide sale campaign due to adverse weather in the last few months.

Revenues from royalties, licensing and other agreements amounted to &8 million in the first quarter of 2018, compared with &3.8 million in the first quarter last year. This item included &4 million collected under the agreement signed with Seattle Genetics in February.

As a result, group EBITDA amounted to €-0.9 million in the first quarter of 2018.



The group reported a net attributable loss of \in -1.3 million in the first quarter of 2018, which represents a 45% improvement on the \in -2.4 million recorded in the first quarter of 2017.

About PharmaMar


PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumor drugs obtained from the sea. PharmaMar has a rich pipeline of pre-clinical candidates and a major R&D program. The company develops and markets YONDELIS® in Europe and has three other compounds in clinical development for treating solid and hematological tumors: plitidepsin, PM1183 and PM184. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, Austria, the United Kingdom, Belgium and the USA. PharmaMar also has a majority stake in other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website: www.pharmamar.com

Important note

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe for shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

Further information from:

Alfonso Ortín – Communications Director <u>aortin@pharmamar.com</u> Paula Fernández – Media Relations Manager <u>pfalarcon@pharmamar.com</u>











Investor relations:

José Luis Moreno-Investor Relations and Capital Markets Director

investorrelations@pharmamar.com

Phone: +34 914444500

For more information, visit our website: www.pharmamar.com

###